CD274 and lung adenocarcinoma: As previously shown21 among 30 396 lung adenocarcinomas, we reported the prevalence of CD274 copy number gains defined as CD274 copy number of at least specimen ploidy +1, specimen ploidy +2, specimen ploidy +3, and specimen ploidy +4 as 15%, 5.1%, 1.8%, and 0.9%, respectively.